Drug Discovery Weekly — 2026-03-27
Merck is nearing a roughly $6.7 billion all-cash acquisition of Terns Pharma to bolster its oncology and hematology portfolio — the largest pharma deal of the week. On the regulatory front, Daiichi Sankyo and AstraZeneca's Enhertu continues to rack up new approvals in Japan. In the business arena, Gilead Sciences also closed a $2+ billion buyout of Ouro Medicines to expand its immunology pipeline, as biotech dealmaking accelerates through Q1 2026.
Drug Discovery Weekly — 2026-03-27
FDA & Regulatory Spotlight
The Fierce Pharma regulatory tracker for H1 2026 recorded multiple new nods this week, with activity across oncology and beyond. No Complete Response Letters or Advisory Committee votes with confirmed post-March 20 dates were available in this cycle's research; the items below reflect the most current verified regulatory intelligence.
Enhertu (Daiichi Sankyo / AstraZeneca)
- Indication: Multiple oncology indications (HER2-targeting antibody-drug conjugate)
- Decision/Status: New regulatory approvals secured in Japan (Q1 2026, tracked in H1 2026 regulatory tracker)
- Significance: Enhertu continues its global regulatory march, cementing its status as one of the most versatile ADCs in oncology. Each new geographic nod expands patient access and validates the HER2-directed ADC platform more broadly.
Boehringer Ingelheim — Lung Cancer & Pulmonary Fibrosis Launches
- Indication: Non-small cell lung cancer and pulmonary fibrosis
- Decision/Status: Two medicines with FDA Breakthrough Therapy designation successfully launched in 2025; Boehringer confirmed commercial performance in its March 25, 2026 annual results announcement
- Significance: Boehringer Ingelheim delivered on its late-stage pipeline commitments, growing Human Pharma sales by 7.3% in 2025. Both launches carried Breakthrough Therapy designations, underscoring the FDA's expedited pathway as a strategic lever for high-unmet-need diseases.
Ophthalmology Pipeline — Q2 2026 Regulatory Milestones
- Indication: Various ophthalmic conditions
- Decision/Status: Multiple Phase 3 readouts, regulatory filings, and trial enrollments expected through June 30, 2026
- Significance: Ophthalmology Times published a forward-looking pipeline tracker (March 27, 2026) identifying key PDUFA-adjacent dates and Phase 3 data windows for eye disease programs. Retinal and dry eye disease assets are among those flagged for near-term catalysts.
Clinical Trial Milestones
Hengrui Pharma Global Pipeline Expansion — Multiple Phases
- Sponsor: Hengrui Pharma
- Target/Mechanism: Broad innovative portfolio (oncology, immunology, metabolic disease, and beyond)
- Result: In its 2025 annual results (released March 26, 2026), Hengrui reported 28 drug candidates entering Phase III, 61 progressing to Phase II, and 28 new molecular entities entering Phase I for the first time. The company now has over 100 proprietary innovative products in clinical development.
- What's Next: Hengrui's aggressive clinical expansion positions it as a major supplier of late-stage licensing assets to Western pharma — several candidates are expected to generate partnership interest in H2 2026.
BIO-Europe Spring Clinical Partnerships — Shifting Deal Structures
- Sponsor: Industry-wide (multiple companies represented at BIO-Europe Spring 2026)
- Target/Mechanism: Various; conference focused on late-stage asset partnerships
- Result: Industry leaders at BIO-Europe Spring 2026 (reported March 25, 2026) flagged that geopolitical uncertainty and scarcity of late-stage assets are reshaping how clinical-stage partnerships are structured — shifting toward risk-sharing models rather than traditional upfront licensing.
- What's Next: Expect more co-development and profit-sharing structures to emerge in H2 2026 deal announcements, particularly for assets in Phase II/III transition.
Biopharma Funding — IQVIA 2025 Retrospective
- Sponsor: Industry-wide analysis (IQVIA)
- Target/Mechanism: Sector-wide capital allocation trends
- Result: Biopharma funding fell 20% in 2025, reversing the post-pandemic recovery. IPO activity hit its lowest level in 10 years. However, companies doubled down on large individual bets, concentrating capital in fewer, higher-conviction programs.
- What's Next: The funding contraction will likely amplify M&A appetite in 2026, as cash-constrained biotechs seek acquirers for late-stage assets.
Pipeline & Discovery
- Innovative Biotech Companies of 2026 — Enveda, Faeth, Gilgamesh, Argo (Fast Company / Multiple Companies): Fast Company's 2026 Most Innovative Companies list (published March 24, 2026) spotlighted four biotechs reshaping drug discovery: Enveda Biosciences (natural product-derived small molecules using AI-powered metabolomics), Faeth Therapeutics (precision nutrition combined with cancer therapy), Gilgamesh Pharma (novel psychedelic-derived neuropsychiatry drugs), and Argo Biopharma (emerging modality platform). Each represents a distinct frontier in how discovery pipelines are being built beyond traditional medicinal chemistry.
- Most Innovative Pharma Companies of 2026 — Vertex, Bayer, Alnylam, Sanofi (Fast Company / Multiple Companies): A companion Fast Company list (March 24, 2026) recognized Vertex Pharmaceuticals, Bayer, Alnylam Pharmaceuticals, and Sanofi as leaders in medicines and therapeutics innovation. Alnylam's recognition underscores the continued maturation of RNA interference (RNAi) as a therapeutic modality, while Vertex's inclusion highlights its dominance in precision medicine for rare diseases including cystic fibrosis and sickle cell.
Deals & Business
- Merck acquires Terns Pharma for ~$6.7 billion: Merck is nearing a roughly $6.7 billion all-cash deal to acquire Terns Pharma, according to Reuters and Axios (March 25, 2026). Terns focuses on rare blood and bone cancer. This is Merck's third deal aimed at filling a looming pipeline gap as key Keytruda patents approach expiration. Merck executives signaled at a post-announcement briefing that the company is still actively looking for additional oncology and hematology targets.
- Gilead Sciences acquires Ouro Medicines for $2+ billion: Gilead Sciences announced on March 23, 2026 that it will acquire privately held Ouro Medicines in a deal worth more than $2 billion. The acquisition is designed to expand Gilead's pipeline of immune disorder drugs, extending the company's push into immunology beyond its historical HIV and hepatitis franchises.
- **Novartis acquires Excellergy for up to $2
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Create your own signal
Describe what you want to know, and AI will curate it for you automatically.
Create SignalPowered by
